Investigating how NFIB-MAST1 signaling affects resistance to cisplatin in small cell lung cancer.
The role of NFIB-MAST1 signaling in mediating adaptive cisplatin resistance in SCLC
This study is looking at how small cell lung cancer cells become resistant to cisplatin, a common chemotherapy drug, to help find better treatment options for patients like you.
Quick facts
| Grant type | R37 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Texas Hlth Science Center NIH-funded |
| Lab location | 1 site (San Antonio, United States) |
| Project ID | NIH-10880050 on NIH RePORTER |
What this research studies
This research focuses on understanding how small cell lung cancer (SCLC) cells develop resistance to cisplatin, a commonly used chemotherapy drug. The team is using advanced techniques, including kinome-wide shRNA screening and patient-derived tumor models, to identify key signaling pathways involved in this resistance. By studying the role of the MAST1 protein and its interaction with the NFIB protein, the researchers aim to uncover mechanisms that could lead to improved treatment strategies for patients with SCLC.
Who could benefit from this research
Good fit: Ideal candidates for this research are patients diagnosed with small cell lung cancer who are undergoing treatment with cisplatin.
Not a fit: Patients with other types of lung cancer or those not receiving cisplatin may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to new therapeutic approaches that enhance the effectiveness of cisplatin in treating small cell lung cancer.
How similar studies have performed: Previous research has shown promising results in targeting similar pathways to overcome chemotherapy resistance in various cancers.
Where this research is happening
San Antonio, United States
- University of Texas Hlth Science Center — San Antonio, United States (Active)
Researchers
- Principal investigator: Jin, Lingtao — University of Texas Hlth Science Center
- Study coordinator: Jin, Lingtao
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.